Vespakinin-M Antibody

What is Vespakinin-M and what is its molecular structure?

Vespakinin-M (VK) is a natural peptide isolated from the venom of Vespa magnifica (Smith, 1852). This bioactive peptide has been extensively studied for its neuroprotective properties. Structurally, VK is a 12-amino acid peptide with the sequence Gly-Arg-Pro-Hyp-Gly-Phe-Ser-Pro-Phe-Arg-Ile-Asp, confirmed through Edman sequencing and mass spectrometry (MS/MS). The MS/MS analysis identifies a quasi-molecular ion at m/z 1361.6854 . Understanding this precise molecular structure is crucial for researchers designing experimental protocols involving VK antibodies, as it defines epitope recognition parameters and potential cross-reactivity issues.

What are the primary applications of Vespakinin-M antibody in neuroscience research?

Vespakinin-M antibody finds principal applications in neuroscience research focusing on ischemic stroke models and neuroprotective mechanisms. The antibody can be utilized in ELISA and Western Blot techniques as indicated by product specifications . Key applications include:

• Detecting and quantifying VK penetration across the blood-brain barrier in stroke models

• Visualizing VK distribution in cortical, hippocampal, and striatal regions of the brain

• Monitoring VK-induced changes in oxidative stress markers and inflammatory cytokines

• Examining VK interaction with bradykinin receptor 2 (B2R)

• Studying VK-mediated activation of PI3K-AKT and inhibition of IκBα-NF-κB signaling pathways

These applications are particularly valuable in research investigating neuroprotective mechanisms, as VK has demonstrated significant efficacy in reducing infarct volume and improving functional recovery in stroke models .

What technical specifications should researchers know about commercial Vespakinin-M antibodies?

When selecting a Vespakinin-M antibody for research applications, investigators should consider the following technical specifications based on commercially available products:

Researchers should note that the antibody is specifically raised against the recombinant Vespa mandarinia Vespakinin-M protein, which may affect cross-reactivity with Vespakinin-M from other Vespa species. Commercial kits typically include positive control antigens (200μg) and pre-immune serum as negative control to facilitate experimental validation .

How can Vespakinin-M antibody be used to study blood-brain barrier penetration mechanisms?

Investigating VK's blood-brain barrier (BBB) penetration is critical for understanding its neuroprotective effects. Methodological approaches using VK antibody include:

The most effective protocol involves using FITC-labeled VK administered to stroke mice followed by antibody-based detection methods. Studies have demonstrated that VK can cross the BBB, particularly in regions where the barrier is compromised by ischemic injury. Researchers can collect brain tissue at various time points (30, 60, 90, and 120 min post-administration) and use fluorescence imaging combined with VK antibody-based immunohistochemistry to quantify distribution patterns .

For cellular-level analysis, researchers can employ the oxygen-glucose deprivation/reoxygenation (OGD/R) model in hippocampal neuron cells (such as HT22 cells) with FITC-labeled VK. Live-cell imaging has confirmed that VK (7.35 μM) partially crosses the cell membrane in OGD/R-treated neurons, suggesting its potential as a cell-penetrating peptide under ischemic conditions . This methodology allows for real-time tracking of VK movement across cellular barriers.

These approaches are important because the data confirms VK penetrates compromised BBB in stroke models and accumulates in critical brain regions (cortex, hippocampus, and striatum) affected by ischemic injury .

What methodological approaches can quantify the neuroprotective effects of Vespakinin-M in stroke models?

Researchers can employ several complementary methodologies to quantify VK's neuroprotective effects:

• Infarct Volume Assessment: Using either 2,3,5-triphenyltetrazolium chloride (TTC) staining or magnetic resonance imaging (MRI). Studies have shown VK (150 and 300 μg/kg, i.p.) significantly reduces infarct volume in middle cerebral artery occlusion/reperfusion (MCAO/R) mouse models .

• Neurological Function Testing Battery:

  • Longa test: Evaluates limb mobility deficits

  • Rotarod test: Assesses motor coordination

  • Grip strength test: Measures sensorimotor function

  • Morris water maze test: Quantifies spatial learning and memory recovery

• Oxidative Stress Markers:

  • Superoxide dismutase (SOD) activity

  • Lipid peroxide (LPO) levels

  • Malondialdehyde (MDA) concentration

  • Reactive oxygen species (ROS) quantification using DCFH-DA

• Energy Metabolism Parameters:

  • Adenosine triphosphate synthase (ATPase) activity

  • Lactic acid (LD) content

  • Mitochondrial oxygen consumption rate

  • Extracellular acidification rate (measure of glycolysis)

• Blood-Brain Barrier Integrity:

  • Evans blue extravasation method

  • Tight junction protein expression via Western blot with appropriate antibodies

These methodologies have revealed that VK treatment significantly improves neurological outcomes, decreases oxidative stress markers, and enhances energy metabolism in ischemic stroke models compared to vehicle-treated controls .

How can researchers investigate the signaling pathways affected by Vespakinin-M using antibody-based techniques?

VK influences multiple signaling pathways that contribute to its neuroprotective effects. Researchers can use the following antibody-based approaches to investigate these mechanisms:

• PI3K-AKT Pathway Analysis:

  • Western blotting to assess phosphorylation states of PI3K and AKT

  • Immunoprecipitation to identify protein interactions within the pathway

  • Immunohistochemistry to visualize pathway activation in specific brain regions

• IκBα-NF-κB Signaling Investigation:

  • Western blotting for phosphorylated IκBα and nuclear translocation of NF-κB

  • Chromatin immunoprecipitation (ChIP) to evaluate NF-κB binding to target gene promoters

  • ELISA-based transcription factor activity assays

• Bradykinin Receptor 2 (B2R) Interaction Studies:

  • Co-immunoprecipitation with VK antibody and B2R antibody

  • Proximity ligation assay to visualize VK-B2R interactions in situ

  • Receptor antagonist studies using HOE140 to validate functional interactions

• Apoptosis Pathway Investigation:

  • Mouse Apoptosis Signaling Pathway Array to screen for changes in 17 phosphorylated or cleaved apoptotic factors

  • Caspase activation assays combined with Western blotting

Research has demonstrated that VK treatment reduces neuroinflammation and apoptosis through activating PI3K-AKT and inhibiting IκBα-NF-κB signaling . The B2R antagonist HOE140 counteracts VK's neuroprotective effects, confirming the importance of VK-B2R interaction in stroke therapy .

What are the optimal experimental conditions for using Vespakinin-M antibody in Western blot applications?

For optimal Western blot detection of Vespakinin-M, researchers should consider the following protocol parameters:

• Sample Preparation:

  • For brain tissue: Homogenize in RIPA buffer containing protease and phosphatase inhibitors

  • For cell cultures: Lyse cells directly in sample buffer after appropriate treatments

  • Protein concentration determination using Bradford or BCA assay

• Gel Electrophoresis Parameters:

  • Use Tris-Tricine gels (16-20%) for optimal separation of small peptides like VK

  • Load 20-50 μg of total protein per lane

  • Include positive control (provided 200μg antigen) and negative control (pre-immune serum)

• Transfer Conditions:

  • Use PVDF membrane (0.2 μm pore size) for small peptides

  • Transfer at low voltage (30V) overnight at 4°C

  • Verify transfer efficiency with Ponceau S staining

• Antibody Dilutions and Incubation:

  • Primary antibody (VK antibody): 1:500 to 1:2000 dilution

  • Secondary antibody: 1:5000 to 1:10000 dilution of HRP-conjugated anti-rabbit IgG

  • Blocking: 5% non-fat dry milk or BSA in TBST, 1 hour at room temperature

  • Primary antibody incubation: Overnight at 4°C

  • Secondary antibody incubation: 1 hour at room temperature

• Detection Method:

  • Enhanced chemiluminescence (ECL) for standard applications

  • Fluorescent secondary antibodies for multiplexing with other proteins of interest

These conditions should be optimized based on specific experimental requirements and sample types. When studying VK's effects on signaling pathways, researchers should also include antibodies against phosphorylated and total forms of relevant proteins in the PI3K-AKT and IκBα-NF-κB pathways .

What controls and validation steps are necessary when using Vespakinin-M antibody in neurological research?

Proper experimental controls and validation steps are essential for generating reliable data with VK antibody:

• Antibody Validation Controls:

  • Positive control: Use the provided 200μg antigen from the commercial kit

  • Negative control: Employ the provided pre-immune serum

  • Peptide competition assay: Pre-incubate antibody with excess VK peptide to confirm specificity

  • Knockout/knockdown validation: If possible, use samples lacking VK as negative controls

• Experimental Controls for Stroke Research:

  • Sham-operated animals: Essential for baseline comparisons

  • Vehicle-treated stroke animals: Critical for assessing treatment effects

  • Dose-response studies: Test multiple VK concentrations (e.g., 150 and 300 μg/kg)

  • Time course experiments: Evaluate outcomes at different time points post-stroke

• Pathway Analysis Controls:

  • Pathway inhibitors: Use specific inhibitors for PI3K-AKT pathway

  • Receptor antagonist: Include HOE140 (B2R antagonist) to block VK effects

  • Positive controls: Include known activators of the pathways of interest

• BBB Penetration Validation:

  • FITC-labeled VK tracking at multiple time points (0, 30, 60, 90, and 120 min)

  • Evans blue extravasation assay to verify BBB integrity

  • Immunohistochemistry to confirm localization in specific brain regions

• Behavioral Assessment Controls:

  • Pre-training baseline measurements

  • Blinded assessment to prevent bias

  • Multiple behavioral tests to comprehensively evaluate neurological function

These controls and validation steps ensure that observed effects are specifically attributed to VK and its interaction with target receptors and pathways, rather than experimental artifacts or non-specific antibody binding.

How should researchers approach troubleshooting when using Vespakinin-M antibody in different applications?

When encountering challenges with VK antibody applications, researchers should implement the following systematic troubleshooting approach:

• Western Blot Issues:

  • Weak or no signal: Increase antibody concentration, extend incubation time, or enhance detection system sensitivity

  • High background: Use more stringent washing steps, increase blocking agent concentration, or reduce antibody concentration

  • Multiple bands: Verify sample integrity, optimize gel percentage, or perform peptide competition assay to identify specific bands

• Immunohistochemistry Challenges:

  • Poor tissue penetration: Optimize antigen retrieval method, increase incubation time, or use section thickness appropriate for antibody penetration

  • Autofluorescence: Use Sudan Black B treatment or employ spectral unmixing during imaging

  • Inconsistent staining: Standardize fixation protocols and processing times

• ELISA Optimization:

  • Low sensitivity: Adjust antibody concentration, optimize incubation conditions, or employ signal amplification systems

  • High coefficient of variation: Standardize pipetting technique, use calibrated equipment, and ensure consistent washing procedures

  • Matrix effects: Develop appropriate sample dilution strategies or use specialized buffers to minimize interference

• Experimental Design Refinement:

  • Inconsistent results between experiments: Standardize animal models (age, weight, sex), surgical procedures (MCAO duration, anesthesia), and drug administration protocols

  • Conflicting pathway analysis data: Use multiple complementary approaches to confirm signaling pathway involvement

  • Variable BBB penetration: Control for stroke severity, as BBB disruption correlates with ischemic damage intensity

When troubleshooting VK experiments, researchers should also consider the peptide's stability characteristics. Studies have shown that VK in PBS is gradually degraded (62.4% degradation at 120 min) and completely degraded in plasma after 120 min . This degradation profile necessitates careful timing of experiments and appropriate sample processing to capture VK-mediated effects.

How should researchers interpret Vespakinin-M concentration-dependent effects in neuroprotection studies?

Interpreting concentration-dependent effects of VK requires careful consideration of multiple parameters:

VK demonstrates dose-dependent neuroprotective effects in stroke models, with studies showing efficacy at 150 and 300 μg/kg (i.p.) in mice . When interpreting concentration-dependent effects, researchers should consider:

• Efficacy vs. Toxicity Balance:

  • Acute toxicity studies demonstrate safety up to 384 mg/kg, with minimal organ effects observed histopathologically

  • Cellular studies indicate growth inhibition in BV2 microglia and HT22 neuronal cells at concentrations of 73.5–735 μM, establishing an upper limit for in vitro work

  • The therapeutic window for in vitro experiments is 0.0735–7.35 μM, where neuroprotective effects occur without toxicity

• Pathway Activation Thresholds:

  • PI3K-AKT pathway activation shows dose-dependency

  • Inhibition of IκBα-NF-κB signaling varies with concentration

  • Researchers should quantify phosphorylation ratios at different VK concentrations to establish activation thresholds

• Functional Recovery Metrics:

  • Infarct volume reduction correlates with VK dose

  • Neurological function tests (Longa test, rotarod test, grip test, Morris water maze) show varying sensitivity to different VK concentrations

  • Mortality differences between treatment groups (MCAO: 29.06% vs. VK-300: 18.75%) suggest dose-dependent survival benefits

• Temporal Considerations:

  • VK degradation kinetics (complete degradation in plasma by 120 min) affect interpretation of concentration-dependent effects

  • Time-course experiments should account for the pharmacokinetic profile of VK

When interpreting these relationships, researchers should employ appropriate statistical methods including dose-response curve analysis, two-way ANOVA to assess dose and time interactions, and regression analysis to establish concentration-effect relationships.

What advanced imaging techniques can be combined with Vespakinin-M antibody for neurological research?

Researchers can combine several advanced imaging techniques with VK antibody to enhance neurological research:

• Multiphoton Microscopy:

  • Enables deep tissue imaging of VK distribution in intact brain preparations

  • Can be combined with FITC-labeled VK for real-time tracking of peptide movement across the BBB

  • Allows simultaneous visualization of cellular responses (calcium imaging) and VK localization

• Super-Resolution Microscopy:

  • STED (Stimulated Emission Depletion) or STORM (Stochastic Optical Reconstruction Microscopy) can resolve VK-receptor interactions at nanoscale resolution

  • Enables visualization of VK clustering at cellular membranes and subcellular compartments

  • Critical for understanding precise localization patterns in relation to B2R distribution

• In Vivo Imaging Systems:

  • Near-infrared fluorescence imaging for whole-animal VK biodistribution studies

  • FITC-labeled VK has been successfully traced using in vivo imaging systems to detect accumulation in ischemic brain regions

  • Can be combined with MRI to correlate VK distribution with infarct evolution

• Correlative Light and Electron Microscopy (CLEM):

  • Bridges the resolution gap between light and electron microscopy

  • Allows precise localization of VK at subcellular structures like mitochondria, which is relevant given VK's effects on mitochondrial oxygen consumption rate

  • Important for studying VK effects on BBB ultrastructure, including tight junctions and endothelial cell morphology

• Functional Imaging Techniques:

  • Laser speckle contrast imaging (LSCI) to monitor cerebral blood flow changes in VK-treated animals

  • Functional MRI to correlate VK treatment with recovery of brain network activity

  • PET imaging with radiolabeled VK to track whole-body distribution and brain uptake kinetics

These advanced imaging approaches, when combined with specific VK antibody detection, provide comprehensive insights into the spatial, temporal, and functional aspects of VK's neuroprotective mechanisms in stroke models.

How can researchers integrate Vespakinin-M antibody studies with broader neurodegenerative disease research?

VK antibody research can be strategically integrated with broader neurodegenerative disease studies through several approaches:

• Extending VK Research to Other Neurodegenerative Models:

  • Alzheimer's disease: Investigate VK's effects on amyloid-β-induced neurotoxicity and tau hyperphosphorylation

  • Parkinson's disease: Examine VK's potential to mitigate α-synuclein aggregation and dopaminergic neuron loss

  • ALS: Explore VK's anti-inflammatory properties in motor neuron protection

• Mechanism-Based Integration:

  • Oxidative stress: VK's demonstrated antioxidant properties (increasing SOD activity, decreasing MDA and LPO levels) are relevant across neurodegenerative conditions

  • Neuroinflammation: VK's effects on microglial activation and inflammatory cytokine production address a common pathological mechanism

  • Mitochondrial dysfunction: VK's ability to enhance mitochondrial oxygen consumption rate and ATP production targets a central feature of neurodegeneration

• Pathway-Focused Research:

  • PI3K-AKT pathway: Given VK's activation of this pathway , researchers can explore its effects on downstream targets critical in neurodegeneration, such as GSK3β and mTOR

  • NF-κB signaling: VK's inhibition of the IκBα-NF-κB pathway has implications for inflammatory gene expression patterns relevant to multiple neurodegenerative disorders

  • Bradykinin receptor signaling: Expand VK-B2R interaction studies to examine effects on blood-brain barrier integrity in various neurodegenerative conditions

• Translational Research Approaches:

  • Biomarker development: Use VK antibody to detect endogenous peptides with similar structures in human samples

  • Drug delivery systems: Leverage VK's BBB-penetrating properties to develop targeted delivery vehicles for neurodegenerative disease therapeutics

  • Combination therapies: Investigate synergistic effects between VK and established neuroprotective agents

By integrating VK antibody research with these broader approaches, researchers can capitalize on the peptide's unique neuroprotective mechanisms to advance understanding and treatment strategies across the spectrum of neurodegenerative disorders.

What emerging technologies might enhance the utility of Vespakinin-M antibody in neurological research?

Several emerging technologies show promise for enhancing VK antibody applications in neurological research:

• Single-Cell Technologies:

  • Single-cell proteomics to detect VK binding partners at individual cell resolution

  • Single-cell transcriptomics to identify gene expression changes in response to VK treatment

  • These approaches would reveal cell type-specific responses to VK, particularly in heterogeneous brain tissue

• Antibody Engineering Advances:

  • Development of bispecific antibodies targeting both VK and B2R to study their interaction dynamics

  • Creation of nanobodies against VK with enhanced BBB penetration for in vivo imaging

  • Engineering antibody fragments for improved penetration into brain tissue sections

• Spatial Biology Platforms:

  • Spatial transcriptomics combined with VK antibody immunohistochemistry to correlate VK localization with regional gene expression profiles

  • Mass cytometry imaging to simultaneously detect multiple signaling proteins alongside VK in tissue sections

  • These methods would provide unprecedented insight into the spatial context of VK activity in the brain

• CRISPR-Based Approaches:

  • Development of CRISPR activation/inhibition systems to modulate B2R expression in specific cell types

  • Engineering reporter cell lines with fluorescent tags on key components of PI3K-AKT and IκBα-NF-κB pathways

  • These systems would enable precise manipulation of VK's molecular targets

• Artificial Intelligence Applications:

  • Machine learning algorithms to predict VK binding sites and interaction partners

  • Automated image analysis for quantifying VK distribution in complex brain tissue preparations

  • AI-augmented molecular dynamics simulations of VK-B2R interactions

These emerging technologies would significantly enhance researchers' ability to study VK's neuroprotective mechanisms at molecular, cellular, and tissue levels with unprecedented precision and throughput.

How might comparative studies between Vespakinin-M and other wasp venom peptides inform therapeutic development?

Comparative studies between VK and other wasp venom peptides offer valuable insights for therapeutic development:

• Structure-Activity Relationship Analysis:

  • Comparing the 12-amino acid sequence of VK (Gly-Arg-Pro-Hyp-Gly-Phe-Ser-Pro-Phe-Arg-Ile-Asp) with related peptides to identify critical residues for neuroprotection

  • Systematic alanine scanning mutagenesis using synthetic peptide variants and antibody detection to map functional domains

  • These approaches would guide rational design of more stable and potent analogs

• Comparative Receptor Binding Studies:

  • Investigating the specificity of VK for B2R compared to other bradykinin-like peptides from venoms

  • Competitive binding assays using VK antibody to quantify relative affinities

  • Receptor subtype selectivity profiles to identify unique therapeutic advantages of VK

• Pharmacokinetic/Pharmacodynamic Comparisons:

  • Evaluating BBB penetration efficiency of VK versus other venom peptides

  • Comparing plasma stability profiles (VK is completely degraded in plasma after 120 min) to identify more stable candidates

  • Assessment of dose-response relationships across different venom peptides

• Combinatorial Therapeutic Approaches:

  • Testing synergistic effects between VK and other venom peptides with complementary mechanisms

  • Using VK antibody-based pulldown assays to identify novel interaction partners

  • Development of multi-peptide formulations targeting different aspects of stroke pathophysiology

• Translational Model Comparisons:

  • Evaluating efficacy across different stroke models (MCAO/R, thromboembolic, hemorrhagic)

  • Cross-species validation studies (rodent to larger animals)

  • Assessment of therapeutic windows for various venom peptides

These comparative studies would not only advance basic understanding of venom peptide pharmacology but also accelerate the development of optimized therapeutics for stroke and other neurological disorders based on naturally occurring peptide structures.